Ohio State University CRS*

Columbus, Ohio 43212

3 studies enrolling now · 24 studies all time

What they study most

Cardiovascular Diseases, HIV, HIV Infection, HIV Infections, HIV-1, HIV-1-infection, Hepatitis B, Hepatitis C, MPOX, Major Depressive Disorder, Mild Neurocognitive Disorder, Sexually Transmitted Diseases

Studies at this site

• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) — Recruiting now
• Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1 — Recruiting now
• Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV — Paused
• The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE — Running, not enrolling
• Study of Tecovirimat for Human Mpox Virus — Stopped early
• A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 Infection — Starting soon
• Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men — Completed
• Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy — Paused
• Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults — Completed
• B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B — Completed
• Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1 — Completed
• Pharmacokinetics and Safety of SAR441236 — Stopped early
• HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) Vaccine Study — Completed
• Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND) — Completed
• Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART) — Completed
• Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin — Completed
• Optimizing Treatment for Treatment-Experienced, HIV-Infected People — Completed
• Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women — Completed
• Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection — Completed
• Evaluating the Safety and Efficacy of Romidepsin in Combination With Antiretroviral Therapy in HIV-Infected Adults With Suppressed Viral Load — Completed
• Safety and Effectiveness of Low-Dose Methotrexate for Reducing Inflammation in HIV-Infected Adults on ARV Medications — Completed
• Safety and Effectiveness of the Oral HIV Entry Inhibitor Vicriviroc in HIV Infected Patients — Completed
• Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF) — Completed
• Differences in Blood Levels of Lopinavir/Ritonavir in HIV Infected Men and Women — Completed